SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person *
Burnell Thomas W.
(Last) (First) (Middle)
C/O INTERPACE BIOSCIENCES, INC.
2001 ROUTE 46 WATERVIEW PLAZA, SUITE 310
(Street)
PARSIPPANY NJ 07054
(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading Symbol
INTERPACE BIOSCIENCES, INC. [IDXG]

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director
10% Owner
X Officer (give title below)
Other (specify below)
CEO, President & Chairman

6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/20/2026		M		1,966,763[(1)]	A	$0	2,037,645	D	
Common Stock	08/20/2026		F		581,718[(2)]	D	$1.61	1,455,927	D	
Common Stock								10,885	I	By spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	[(3)]	08/20/2026		A		1,966,763		[(4)]	[(4)]	Common Stock	1,966,763	$0	1,966,763	D	
Restricted Stock Units	[(3)]	08/20/2026		M			1,966,763	[(4)]	[(4)]	Common Stock	1,966,763	$0	0	D	
Stock Option (right to buy)	$2.02	08/20/2026		A		554,018		[(5)]	08/20/2036	Common Stock	554,018	$0	554,018	D	

Explanation of Responses:

1. Represents the conversion upon vesting of restricted stock units ("RSUs") into shares of common stock of Interpace Biosciences, Inc. (the "Issuer"). On August20, 2026, the Reporting Person was granted 1,966,763 RSUs, all of which vested upon grant and which amount includes an amount intended to satisfy the Reporting Person's tax obligations arising from the award.

2. Represents shares returned to the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person received the net number of shares after the shares were returned to the Issuer to satisfy applicable tax withholding obligations.

3. Each RSU represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc.

4. On August 20, 2026, the Reporting Person was granted 1,966,763 RSUs, all of which vested upon grant and which amount includes an amount intended to satisfy the Reporting Person's tax obligations arising from the award.

5. The options will vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date.

/s/ Thomas W. Burnell 08/20/2026
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.